New Insights into the Functions of MicroRNAs in Cardiac Fibrosis: From Mechanisms to Therapeutic Strategies

Genes (Basel). 2022 Aug 4;13(8):1390. doi: 10.3390/genes13081390.

Abstract

Cardiac fibrosis is a significant global health problem associated with almost all types of heart disease. Extensive cardiac fibrosis reduces tissue compliance and contributes to adverse outcomes, such as cardiomyocyte hypertrophy, cardiomyocyte apoptosis, and even heart failure. It is mainly associated with pathological myocardial remodeling, characterized by the excessive deposition of extracellular matrix (ECM) proteins in cardiac parenchymal tissues. In recent years, a growing body of evidence demonstrated that microRNAs (miRNAs) have a crucial role in the pathological development of cardiac fibrosis. More than sixty miRNAs have been associated with the progression of cardiac fibrosis. In this review, we summarized potential miRNAs and miRNAs-related regulatory mechanisms for cardiac fibrosis and discussed the potential clinical application of miRNAs in cardiac fibrosis.

Keywords: cardiac fibrosis; cardiac fibrosis-related signaling pathways; clinical application; miRNAs.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Extracellular Matrix Proteins / metabolism
  • Fibrosis
  • Heart Failure* / genetics
  • Heart Failure* / therapy
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Myocardium / metabolism

Substances

  • Extracellular Matrix Proteins
  • MicroRNAs

Grants and funding

This study was funded by grants from the National Natural Science Foundation of China (Grant No. 81700300) and the Innovation Team Fund Project of Hubei Province (WJ2021C001).